Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87)

Biological Chemistry

Volumn 382, Issue 8, 2001, Pages 1197-1205

  Magdolen, V ^a   Burgle M ^a   Arroyo de Prada, N ^a   Schmiedeberg, N ^a   Riemer, C ^a   Schroeck, F ^a   Kellermann, J ^a   Degitz, K ^a   Wilhelm, O G ^a   Schmitt, M ^a   Kessler, H ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

D amino acid; Peptides; Protease; Receptor; Tumor invasion; Urokinase

Indexed keywords

AMINO ACID; CELL SURFACE RECEPTOR; DEXTRO AMINO ACID; FIBRIN; LIGAND; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE; UROKINASE RECEPTOR; CYCLO(19,31) UROKINASE TYPE PLASMINOGEN ACTIVATOR (19 31); CYCLO(19,31)-UROKINASE-TYPE PLASMINOGEN ACTIVATOR (19-31); CYCLOPEPTIDE; PEPTIDE FRAGMENT; PLASMINOGEN; PLASMINOGEN ACTIVATOR, UROKINASE RECEPTORS;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INVASION; CELL INVASION; CELL PROLIFERATION; CELL STRAIN U937; CELL SURFACE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG INHIBITION; DRUG TARGETING; FIBRINOLYSIS; HUMAN; HUMAN CELL; METASTASIS; MOLECULAR WEIGHT; PATHOPHYSIOLOGY; PHYSIOLOGY; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN INTERACTION; RECEPTOR BINDING; TISSUE REPAIR; TUMOR CELL; WOUND HEALING; AMINO ACID SUBSTITUTION; BINDING COMPETITION; CELL CULTURE; CELL MEMBRANE; DRUG ANTAGONISM; DRUG EFFECT; IC 50; METABOLISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

AMINO ACID SUBSTITUTION; BINDING, COMPETITIVE; CELL MEMBRANE; CELLS, CULTURED; FIBRIN; HUMANS; INHIBITORY CONCENTRATION 50; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; PLASMINOGEN; RECEPTORS, CELL SURFACE; STRUCTURE-ACTIVITY RELATIONSHIP; URINARY PLASMINOGEN ACTIVATOR;

EID: 17944377395     PISSN: 14316730     EISSN: None     Source Type: Journal    
DOI: 10.1515/BC.2001.150     Document Type: Article

References (49)

1. The plasminogen activation system in tumor growth, invasion, and metastasis
2. The receptor binding sequence of urokinase
3. Synthesis of optically pure α-amino acids via salts of α-amino-β-propiolactone
4. A region in domain II of the urokinase receptor required for urokinase binding
5. Inhibition of the interaction of urokinase (uPA) with its receptor (uPAR, CD87) by synthetic peptides
6. The fluorenylmethoxycarbonyl amino-protecting group
7. A dozen years of retro-in-verso peptidomimetics
8. Flow cytoflurometric analysis of the urokinase receptor (uPAR) on tumor cells by fluorescent uPA-ligand or monoclonal antibody #3936
9. Prevention of metastasis by inhibition of the urokinase receptor
10. The urokinase-type-plasminogen-activator receptor (CD87) is a pleiotropic molecule
11. Synthesis of natural and non natural orthogonally protected lanthionines from N-tritylserine and allo-threonine derivatives
12. Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor
13. Plasminogen binding to cell surfaces
14. Solid phase peptide synthesis utilizing 9-fluorenyl-methoxycarbonyl amino acids
15. Urokinase induces proliferation of human ovarian cancer cells: Characterization of structural elements required for growth factor function
16. Mapping part of the functional epitope for ligand binding on the receptor for urokinase-type plasminogen activator by site-directed mutagenesis
17. High-affinity urokinase receptor antagonists identified with bacteriophage peptide display
18. A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo
19. Solution structure of the aminoterminal fragment of urokinase-type plasminogen activator
20. Backbone dynamics of a two domain protein: 15N relaxation studies of the amino-terminal fragment of urokinase-type plasminogen activator
21. Lantibiotica - Ribosomal synthetisierte Polypeptidwirkstoffe mit Sulfidbrücken und α,β-Didehydroaminosäuren
22. A bifunctional hybrid molecule of the amino-terminal fragment of urokinase and domain II of bikunin
23. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87)
24. Adenovirus-mediated delivery of a uPA/uPAR antagonist suppresses angiogenesis-dependent tumor growth and dissemination in mice
25. High level synthesis of recombinant soluble urokinase receptor (CD87) by ovarian cancer cells reduces intraperitoneal tumor growth and spread in nude mice
26. Systematic mutational analysis of the receptor-binding region of the human urokinase-type plasminogen activator
27. Lanthionine macrocyclisation by in situ activation of serine
28. Solution structures of Fcε RI α-chain mimics: A β-hairpin peptide and its retroenantiomer
29. Isourea-mediated preparation of dehydro amino acids
30. Urokinase receptor antagonists inhibit angiogenesis and primary tumor growth in syngeneic mice
31. Morphological, immunohistochemical, and biochemical characterization of 6 newly established human ovarian carcinoma cell lines
32. Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth
33. A novel type of bifunctional inhibitor directed against proteolytic activity and receptor/ligand Interaction: Cystatin with a urokinase receptor binding site
34. Identification of specific sites involved in ligand binding by photoaffinity labeling of the receptor for the urokinase-type plasminogen activator. Residues located at equivalent positions in uPAR domains I and assembly of a composite ligand-binding site
35. Cycloenantiomerie und Cyclodiastereomerie
36. Lanthionines for solid phase synthesis
37. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis
38. Inhibition of NF-κB-RelA expression by antisense-oligodeoxynucleotides suppresses synthesis of urokinase-type plasminogen activator (uPA) but not its inhibitor PAI-1
39. Biosynthesis and biological activities of lantibiotics with unique post-translational modifications
40. The urokinase plasminogen activator system as a novel target for tumour therapy
41. A facile synthesis of orthogonally protected stereoisomeric lanthionines by regioselective ring opening of serine β-lactone derivatives
42. Topochemische Untersuchungen an Peptidsystemen
43. (4-Aminomethyl)phenylguanidine derivatives as non-peptidic highly selective inhibitors of human urokinase. X-ray crystal structure of an uPA/inhibitor complex at 1.7 Å resolution
44. Inhibition of urokinase by 4-substituted benzo[b]thiophene-2-carboxamidines: An important new class of selective synthetic urokinase inhibitor
45. Urokinase receptor antagonists: Discovery and application to in vivo models of tumor growth
46. An improved synthesis of threo-3-methyl-D-cysteine
47. 3 integrin inhibitor cyclo(-RGDfV-) and its retro-inverso peptide
48. Fmoc-Trp(Boc)-OH: A new derivative for the synthesis of peptides containing tryptophan. Peptides, chemistry and biology
49. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice